DUBLIN – Vifor Pharma Group is paying $60 million, including $30 million up front and $30 million in equity investment, to secure rights to Angion Biomedica Corp.’s hepatocyte growth factor (HGF) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results